Headaches

Disease

Related News

Psychedelic Therapies Show Promise for Depression, Anxiety and Addiction

Clinical trials show psychedelic substances like psilocybin, LSD and MDMA combined with therapy can effectively treat depression, anxiety and addiction. Several substances are in Phase III trials, with esketamine already approved for treatment-resistant depression. Research suggests these treatments may work with fewer doses than traditional medications.

Related Clinical Trials

NCT ID Title Status Phase
NCT07477236

MyVitalC: Sleep and Everyday Headache Management

RECRUITING NA
NCT02638506

RCT Evaluating Intranasal Fentanyl in the Pain Management of Children With Headaches

TERMINATED PHASE4
NCT02285868

ATI Evidence-based Guide Investigating Clinical Services

ACTIVE_NOT_RECRUITING
NCT02270177

Telemedicine Versus Traditional Specialist Consultation for Headache: a Non-inferiority Trial

COMPLETED NA
NCT01667679

Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura

COMPLETED PHASE3
NCT00956969

Stress Management for Chronic Headaches

COMPLETED NA
NCT00921453

Tailored Internet Information Supply for Patients - Part 2

COMPLETED
NCT00484029

Nasal Carbon Dioxide (CO2)for the Treatment of Temporomandibular Disorders (TMD)Related Pain

COMPLETED PHASE2
NCT00475189

Study of Loestrin 24(24 Days of "Real" Pills) Fe Versus Loestrin 1/20 (21 "Real" Pills)

COMPLETED NA
NCT00067249

Women's Use of Alternative Medicine: A Multiethnic Study

COMPLETED